Introduction
One of the provisions of the Patient Protection and Affordable Care Act (PPACA), the comprehensive healthcare reform legislation enacted in 2010, requires private health insurance plans to provide first-dollar coverage (i.e., no copayment, coinsurance or deductible) for preventive healthcare services. 1 This rule requires insurance benefit coverage of contraceptive methods at no out-of-pocket cost to the patient, as long as the contraceptives come from an in-network provider.
The Health Resources and Services Administration (HRSA)-supported health plan coverage guidelines recommend that all FDA approved contraceptive methods (hormonal, barrier, emergency, implantable and sterilization) be covered at no out-of-pocket cost. Plans may still require cost-sharing and reasonable medical management strategies for certain brand name or non-preferred products as long as medically appropriate alternatives are available at no copayment or co-insurance. 1 Except for grandfathered health plans, the contraceptive coverage rule applies as of the first coverage plan year beginning on or after August 1, 2012. For the majority of insurance plans, the first affected plan year began on January 1, 2013.
The stated motivation for lowering cost barriers to contraceptive care is to expand the accessibility and affordability of these services. 1 Preventing unintended pregnancy has several well documented benefits including personal, public health and societal benefits as well as positive economic outcomes. 2, 3, 4 With these goals in mind, a successful mandate should have the effect of promoting greater overall use of contraceptive methods among women of childbearing age who seek to prevent unintended pregnancies.
Objective
To determine whether the mandate has led to a change in contraceptive use in a commerciallyinsured population.
Methods

Study cohort:
De-identified pharmacy and medical claims data for commercially-insured female benefit plan members aged 15 to 49 (as of December 31, 2012) from a large national pharmacy benefit manager (PBM) were used to construct the study cohorts.
Three cohorts were created -from July 2010 to June 2011, July 2011 to June 2012 and from July 2012 to June 2013 -each with members continuously enrolled for the 12-month period. The first 6 months in each of these cohorts (look-back period) was used only to ascertain the longevity of contraceptive use (new vs experienced users) and the next 6 months were used as the main study period. Females with at least one contraceptive claim in the study period and no contraceptive claim in the look-back period were considered new users. Only new users in each of the three 6 months study periods were examined in this study to enable a comparison between refillable and long-acting reversible contraceptives (LARCs).
The two pre-cohorts allowed for better understanding of any underlying secular trends occurring prior to the mandate. The last cohort captured the early experience immediately after implementation of the coverage mandate for the vast majority of health plans.
Member Inclusion Criteria:
• Continuously eligible commercially insured female patients 
Incidence / Initiation Rate:
This measure was calculated by dividing the number of eligible female patients new on contraceptives in the study period by number of eligible female members.
Analysis:
Descriptive statistics were used to examine contraceptive utilization among study patients by type of contraceptives (refillable vs LARC). Logistic regression was used to evaluate the impact of the mandate on change in contraceptive use among commercially-insured female patients.
Results
The Incidence rate 0.51% 0.45% 0.66% -10.3% 44.6% Percent of patients initiating a refillable contraceptive steadily increased during the three study periods with no jump after the mandate. Hence, the increase in refillable use could be a result of a secular trend and not necessarily the mandate. The initiation rate of LARC was significantly higher after the mandate compared to previous periods (OR=1.44, p<0.01, 95% CI =1.36-1.54) (Exhibit 2). 
• This analysis only provides insight into patterns occurring through the first 6 months of 2013. The longer-term impact is unknown.
• LARCs can last between three and five years or more, therefore, the impact of previous years' LARC method utilization on the result was not analyzed in this study. It was assumed that the utilization of LARCs in 2010 or prior would be relatively stable year over year.
Discussion and Implications
The mandate aimed at reducing or eliminating out-of-pocket costs for commercially-insured women seeking contraception. 1 However, utilization did not increase appreciably for refillable contraceptives. The overall incidence rate of refillable contraceptives only increased by 3.8% among women of childbearing age, and this increase was smaller than the increase observed between the periods prior to the implementation of the coverage rule -there was a 4.1% increase from 2011 to 2012. On the other hand, initiation of patients on LARCs increased significantly. The findings could reflect ample access to affordable contraception (e.g., generic oral contraceptives) by the patient population. In such a scenario, removing copayments would do little to tap latent demand. Previous studies have reported relatively soft changes in demand for other types of medication as copayments decrease, consistent with the observations of refillable contraceptives observed in this analysis. 5 It could also be that member out-of-pocket cost may not be the main barrier to greater use of refillable contraception. However, this was not the case with LARCs. For more expensive contraceptive methods such as LARCs, eliminating member cost may successfully eliminate the cost obstacle and thus have a greater impact on utilization than was observed in lower cost methods. Our data have confirmed that removing the cost barrier has an impact on expanding utilization of more expensive contraceptives such as LARCs but not on refillable contraceptives.
Conclusions
Based on this study, the mandate appears to be an inefficient mechanism for improving refillable contraceptive use (apart from secular trends) but has a positive impact on utilization of more expensive and more effective LARC methods. This study serves as an important reminder of the inherent limitations of using financial incentives alone to change the use of healthcare services in certain situations.
